Enlivex Therapeutics Net Worth
Enlivex Therapeutics Net Worth Breakdown | ENLV |
Enlivex Therapeutics Net Worth Analysis
Enlivex Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Enlivex Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Enlivex Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Enlivex Therapeutics' net worth analysis. One common approach is to calculate Enlivex Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Enlivex Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Enlivex Therapeutics' net worth. This approach calculates the present value of Enlivex Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Enlivex Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Enlivex Therapeutics' net worth. This involves comparing Enlivex Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Enlivex Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Enlivex Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Enlivex Therapeutics' net worth research are outlined below:
| Enlivex Therapeutics generated a negative expected return over the last 90 days | |
| Enlivex Therapeutics has some characteristics of a very speculative penny stock | |
| Enlivex Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (29.07 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Enlivex Therapeutics currently holds about 62.48 M in cash with (23.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.4, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Enlivex Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Enlivex Adopts Bitcoin Treasury Reserve Strategy |
Enlivex Therapeutics Quarterly Good Will |
|
Enlivex Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Enlivex Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Enlivex Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 21st of June 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Enlivex Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Enlivex Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Enlivex Therapeutics backward and forwards among themselves. Enlivex Therapeutics' institutional investor refers to the entity that pools money to purchase Enlivex Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Activest Wealth Management | 2024-06-30 | 1000 | Srs Capital Advisors Inc | 2024-06-30 | 615 | Advisor Group Holdings, Inc. | 2024-06-30 | 400 | Jpmorgan Chase & Co | 2024-06-30 | 231 | Ubs Group Ag | 2024-06-30 | 16.0 | Global Retirement Partners, Llc. | 2024-09-30 | 11.0 | Qube Research & Technologies | 2024-06-30 | 1.0 | Susquehanna International Group, Llp | 2024-06-30 | 0.0 | Simplex Trading, Llc | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 2.1 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 489.8 K |
Follow Enlivex Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 19.89 M.Market Cap |
|
Project Enlivex Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.79) | (0.83) | |
| Return On Capital Employed | (0.96) | (1.00) | |
| Return On Assets | (0.79) | (0.83) | |
| Return On Equity | (0.97) | (1.01) |
When accessing Enlivex Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Enlivex Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Enlivex Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Enlivex Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Enlivex Therapeutics. Check Enlivex Therapeutics' Beneish M Score to see the likelihood of Enlivex Therapeutics' management manipulating its earnings.
Evaluate Enlivex Therapeutics' management efficiency
Enlivex Therapeutics has return on total asset (ROA) of (0.2746) % which means that it has lost $0.2746 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6117) %, meaning that it created substantial loss on money invested by shareholders. Enlivex Therapeutics' management efficiency ratios could be used to measure how well Enlivex Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.83 in 2024. Return On Capital Employed is likely to drop to -1 in 2024. At this time, Enlivex Therapeutics' Non Current Assets Total are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 187.9 K in 2024, whereas Total Assets are likely to drop slightly above 30.6 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.62 | 1.54 | |
| Tangible Book Value Per Share | 1.62 | 1.54 | |
| Enterprise Value Over EBITDA | (1.78) | (1.87) | |
| Price Book Value Ratio | 1.67 | 1.58 | |
| Enterprise Value Multiple | (1.78) | (1.87) | |
| Price Fair Value | 1.67 | 1.58 | |
| Enterprise Value | 50.3 M | 41.9 M |
The decision-making processes within Enlivex Therapeutics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Return On Equity (0.61) |
Enlivex Therapeutics Earnings per Share Projection vs Actual
Enlivex Therapeutics Corporate Management
| Veronique AmorBaroukh | Senior Operations | Profile | |
| Shachar CPA | Chief Officer | Profile | |
| Oren Hershkovitz | Chief Officer | Profile | |
| Sigal Arad | Director HR | Profile | |
| Pr MD | Founder Officer | Profile |
Additional Tools for Enlivex Stock Analysis
When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.